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Background: Cholinergic transmission has been implicated in learning, memory and cognition. However, the
cellular effects induced by muscarinic acetylcholine receptors (mAChRs) activation are poorly understood in the
neocortex. We investigated the effects of the cholinergic agonist carbachol (CCh) and various agonists and
antagonists on neuronal activity in rat neocortical slices using intracellular (sharp microelectrode) and field potential
recordings.
Results: CCh increased neuronal firing but reduced synaptic transmission. The increase of neuronal firing was
antagonized by pirenzepine (M1/M4 mAChRs antagonist) but not by AF-DX 116 (M2/M4 mAChRs antagonist).
Pirenzepine reversed the depressant effect of CCh on excitatory postsynaptic potential (EPSP) but had marginal
effects when applied before CCh. AF-DX 116 antagonized the depression of EPSP when applied before or during
CCh. CCh also decreased the paired-pulse inhibition of field potentials and the inhibitory conductances mediated
by GABAA and GABAB receptors. The depression of paired-pulse inhibition was antagonized or prevented by AF-DX
116 or atropine but only marginally by pirenzepine. The inhibitory conductances were unaltered by xanomeline
(M1/M4 mAChRs agonist), yet the CCh-induced depression was antagonized by AF-DX 116. Linopirdine, a selective
M-current blocker, mimicked the effect of CCh on neuronal firing. However, linopirdine had no effect on the
amplitude of EPSP or on the paired-pulse inhibition, indicating that M-current is involved in the increase of
neuronal excitability but neither in the depression of EPSP nor paired-pulse inhibition.
Conclusions: These data indicate that the three effects are mediated by different mAChRs, the increase in firing
being mediated by M1 mAChR, decrease of inhibition by M2 mAChR and depression of excitatory transmission by
M4 mAChR. The depression of EPSP and increase of neuronal firing might enhance the signal-to-noise ratio, whereas
the concomitant depression of inhibition would facilitate long-term potentiation. Thus, this triade of effects may
represent a “neuronal correlate” of attention and learning.
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Considerable evidence indicates a crucial role of acetylcho-
line (ACh)-mediated transmission in learning and memory.
Impairment of cholinergic signalling contributes to cogni-
tive deficits in animal models [1] and diseases such as
schizophrenia and Alzheimer’s Disease [2-4]. Conversely,
drugs that augment cholinergic transmission (e.g. donepezil* Correspondence: rudolf.deisz@charite.de
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reproduction in any medium, provided the origor galatamine) have been shown to improve certain cogni-
tive functions [5,6]. In this context metabotropic ACh
receptors, termed muscarinic ACh receptors (mAChRs) [7]
play a crucial role. Five mAChR subtypes have been cloned
(M1-M5); each consisting of seven highly conserved trans-
membranal segments. A large and more variable intracellu-
lar domain [8] couples the receptor to second messengers
and ion channels via heterotrimeric G-proteins [1,7,9,10].
The mAChRs are now recognized as key targets for
the treatment of different neuropathologies such as
Alzheimer’s Disease, schizophrenia and Parkinson’s DiseaseLtd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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M2 or M4 mAChRs are promising substances [10,11].
However, the similarity in ligand-binding sites between
mAChR subtypes, the paucity of selective agonists/antago-
nists as well as the expression of different subtypes of
mAChRs in a given area constitute major obstacles to de-
lineate cellular effects of a given subtype [1]. The improve-
ment of therapeutic approaches using specific mAChR
modulators is further impeded by a lack of established and
validated protocol to screen efficacy of different mAChR
agonist/antagonist at native receptors in neocortical slices.
Characterization of receptors in a native system is a crucial
issue. For instance, at D2-type dopamine receptors [12] or
AMPA receptors [13], the pharmacology at recombinant
receptors critically depends on the experimental condi-
tions. Thus, the pharmacology of mAChR in heterologous
systems may not necessarily relate to the natively expressed
mAChR [14]. Therefore, to delineate the pharmacology of
mAChRs in the neocortex, the data must be obtained in
the native neocortical slice.
We tried to define simple paradigms to quantify routinely
the efficacy of different mAChR agonists. This should facili-
tate further screening for novel drugs in the neocortex. We
investigated the effects of CCh and various mAChR antago-
nists on several parameters of neuronal excitability and the
synaptic transmission in neocortical layer II/III. We have
chosen layer II/III of neocortex because of the established
expression of M1, M2 and M4 but not M3 and M5 mAChRs
at the mRNA [15] and the protein levels [15-18].
As a first step we tested whether the published effects
obtained under various experimental conditions can be
reproduced. Firstly, in neocortical pyramidal neurones,
ACh or the prototype cholinergic agonist carbamylcho-
line-chloride (carbachol, CCh) depolarizes the membrane
potential and increases action potential (AP) firing [19-21].
Secondly, CCh reduces excitatory postsynaptic potentials
(EPSPs) in neocortical neurons [21,22]. This depressant ef-
fect was reduced by the preferential M1/M4 and M2/M4
mAChRs antagonists (pirenzepine and AFDX 116, respect-
ively) and was not due to activation of nicotinic receptors
[22]. Thirdly, ACh reduces the GABA release in neocortex
via activation of M2 mAChR and to a smaller extent by ac-
tivation of M1 mAChR [23].
Here we show that these 3 effects are mediated by 3
different subtypes of mAChRs allowing screening for
mAChRs subtype-specific agonists/antagonists.
Results
Modulation of neuronal properties and firing behaviour
In control conditions, neurones had a resting membrane
potential (Em) of −76.2 ± 0.4 mV, an input resistance of
20.4 ± 0.8 MΩ and the AP amplitudes averaged
92.4 ± 0.7 mV (n = 92). The slope of neuronal AP firing
was 57.3 ± 1.6 APs/nA in control conditions.Effects of CCh on membrane properties and neuronal firing
Bath application of CCh had no effect on Em (control:
-75.5 ± 0.7 mV, CCh: -74.8 ± 0.7 mV; n = 40, p> 0.05) or
AP amplitudes (control: 89.5 ± 1.2 mV, CCh:
88.5 ± 1.3 mV; n = 40, p> 0.05). However, CCh consis-
tently increased the neuronal input resistance (control:
20.4 ± 1.3 MΩ, CCh: 24.2 ± 1.4 MΩ; n = 40, p< 0.002).
During CCh application a given current injection eli-
cited more APs (Figure 1A, B, C). The slope of neu-
ronal firing averaged 58.4 ± 2.1 APs/nA in control and
increased to 97.8 ± 3.4 APs/nA in the presence of
CCh (n = 40, p< 0.0001), much more than anticipated
from the increase in membrane resistance. The reversibility
of CCh effect on slope of neuronal APs firing was by
66.4± 6.0% after washout (n= 10; Figure 2A). The sub-
rheobase for AP generation was significantly decreased
during perfusion with CCh (control: 0.5± 0.02 nA, CCh:
0.46± 0.02 nA, n=40, p< 0.01).
Pharmacological delineation of the mAChR subtypes involved
Atropine (n= 7) or pirenzepine (n= 7) reversed the CCh-
induced increase of slope of neuronal firing (p< 0.05 vs
CCh alone and p> 0.05 vs. control; not shown). This an-
tagonism was almost complete and indistinguishable from
the reversibility observed after washout (n= 10; p> 0.05;
Figure 2A). However, AFDX did not reverse the CCh-
induced increase of slope of neuronal firing (p> 0.05 vs.
CCh and p< 0.05 vs. control). In fact, the antagonism
observed with AFDX (n = 7) was much smaller than the
reversibility observed after washout (n = 10, p< 0.01;
Figure 2A). In the continuous presence of CCh, the an-
tagonism observed during a co-application of “pirenze-
pine +AFDX” (n = 8) was not different to that obtained
during application of pirenzepine alone (n = 7, p> 0.05;
Figure 2A). This suggests that the slight antagonism
observed during application of AFDX alone is due to
some antagonistic effect of AFDX on M1 mAChR.
The slope of neuronal firing during application of CCh
in atropine-containing (n= 9) or pirenzepine-containing
artificial cerebrospinal fluid (ACSF) (n= 7) is significantly
smaller than that obtained during application of CCh in
standard ACSF (n= 40, p< 0.01; Figure 2B). However, the
slope of neuronal firing during application of CCh added
to an AFDX-containing ACSF (n=7) is not different to
that obtained during application of CCh in standard ACSF
(n= 40, p> 0.05; Figure 2B), i.e. AFDX fails to modify the
CCh-induced effects on firing. To further test the involve-
ment of M1 mAChR in the effects on firing, we applied
xanomeline, a M1/M4 preferring mAChRs agonist [24].
Xanomeline increased the slope of neuronal firing from
57.8± 6.5 APs/nA to 80.4 ± 7.7 APs/nA (n= 11, p< 0.001).
Together these data suggest that CCh exerts its action
on slope of neuronal firing via mAChRs, and in particu-
lar M1 but not M2 or M4 mAChRs.
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Figure 2 Pharmacology of CCh-induced increase in slope of neuronal APs firing. A. Plot of the reversibility (in %) of the CCh-induced
increase in slope of neuronal APs firing after washout or addition of different mAChR antagonists to a CCh-containing ACSF as indicated. Note the
reversibility observed with atropine (n = 7) or pirenzepine (n = 7) was maximal since not different to that observed after washout (n = 10).
However, the reversibility observed with AFDX was much smaller to that observed after washout. The reversibility observed during a co-
application of CCh with “AFDX+ pirenzepine” (n = 8) was not different to that obtained during a co-application of CCh with “pirenzepine alone”
(n = 7). These experiments were performed in STRC. *: p< 0.05 vs. reversibility after washout. B. Plot of the slope of neuronal AP firing during CCh
addition in standard ACSF or in ACSF containing different mAChR antagonists as indicated. Note the slope of neuronal firing during application of
CCh in a atropine-containing (n = 9) or a pirenzepine-containing (n = 7) ACSF is significantly smaller to that obtained during application of CCh in
standard ACSF (n = 40). However, slope of neuronal firing during application of CCh in an AFDX-containing ACSF (n = 7) is not different to that
obtained during application of CCh in standard ACSF (n = 40). These experiments were performed in STRC. The symbols represent: *: p< 0.05 vs.




































Figure 1 CCh and linopirdine effects on neuronal AP firing. A, B. Voltage traces of a neocortical neurone in control condition (A) and in the
presence of 10 μM CCh (B). The traces show voltage responses to current injections of 0.40 and 0.50 nA (durations 600 ms). Note the increased
number of APs in the presence of 10 μM CCh compared to control condition. C, D. Plot of the average number of APs vs. current injection in
control conditions and in the presence of 10 μM CCh (C; n = 40) or 10 μM linopirdine (D, n = 12). These experiments were performed in STRC.
*: p< 0.05 vs. control, ***: p< 0.001 vs. control.
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M-current blockade
To test the involvement of KV7 channels blockade [9] in
the M1 mAChR-mediated increase of neuronal firing, we
applied linopirdine (10 μM), a blocker of KV7 channels
[25]. Bath application of linopirdine had no effect on
AP amplitudes (control: 97.5 ± 1.6 mV, linopirdine:
95.4 ±2.5 mV; n=12, p> 0.05) or on Em (control:
-76.5 ± 1.1 mV, linopirdine: -75.6 ±1.2 mV; n=12, p> 0.05)
as expected since KV7 channels are not activated at
−75 mV [9]. However, linopirdine increased the neuronal
input resistance (control: 17.8± 1.8 MΩ, linopirdine:
28.4 ±3.2 MΩ; n = 12; p< 0.0001).
Linopirdine increased significantly the number of APs at
each current magnitude (Figure 1D). Consequently, the
slope was 58.4±5.1 APs/nA in control and increased to
79.8±7.8 APs/nA in the presence of linopirdine (n=12,
p< 0.002). The sub-rheobase for AP generation was
strongly decreased from 0.58±0.05 nA in control to
0.36±0.03 nA in the presence of linopirdine (n=12,
p< 0.0001).
Bath application of retigabine (10 μM), an activator
of KV7 channels [26], had no effect on AP amplitudes
(control: 95.6± 1.6 mV, retigabine: 95.1 ± 2.8 mV; n=7,
p> 0.05), on Em (control: -81.5± 1.6 mV, retigabine:
-81.9 ± 1.6 mV; n=7, p> 0.05), or on neuronal input resis-
tance (control: 15.3 ± 3.3 MΩ, retigabine: 13.3± 1.8 MΩ;
n = 7; p> 0.05). Retigabine decreased significantly the
number of APs at each current magnitude (not shown).
Consequently, the slope was 53.9±6.1 APs/nA in control
and decreased to 12.2±1.9 APs/nA in the presence of reti-
gabine (n=7, p< 0.0002). The sub-rheobase for AP gener-
ation was increased from 0.81±0.09 nA in control to
0.99±0.12 nA in the presence of retigabine (n=7, p< 0.01).
Modulation of GABAergic transmission
CCh decreases the paired-pulse inhibition of field potentials
Paired-pulse protocols are often used to study GABAergic
inhibition in field potentials [27]. We therefore employed
a paired-pulse protocol as a first step towards studying
CCh modulation of inhibition.
The input–output curves obtained in ITRC (n = 49;
not shown) were qualitatively similar to that obtained in
STRC, except for larger amplitudes of potentials (p
< 0.0001), as expected [28]. The amplitude of the field
potentials decreased significantly in the presence of CCh
(10 μM) at stimulus intensities larger than 0.3 mA (not
shown; n = 49, p< 0.05).
This CCh-induced synaptic depression was antago-
nized by atropine (n = 19). Pirenzepine (n = 15) and
AFDX (n= 16) at least partially reversed the CCh-
induced depression. Linopirdine (n = 10, p> 0.05) and
retigabine (n = 8, p> 0.05) had no effect on synaptic
transmission (data not shown).Paired-pulse stimulations (interpulse intervals: 10 ms -
1 s) were used to determine the magnitude of paired-
pulse depression of the second field potentials (FP2).
Since the apparent time-to-peak of the intracellular
GABAA-mediated response is about 20–30 ms [29], we
focus here on the results obtained for interpulse intervals
of 10–30 ms to investigate GABAA receptor-mediated
inhibition. A high stimulus intensity (1 mA) was used to
maximally activate GABAergic transmission. When two
pulses were delivered 20 ms apart, the mean amplitude
of the FP2 was 25 ± 4% of the amplitude of the first (FP1;
n = 59).
CCh (10 μM) decreased slightly the amplitude of FP1
(to 92 ± 15% of control value; n = 49, p< 0.05; Figure 3A,
B), whereas the amplitude of FP2 increased strongly (to
342 ± 50% of the control value; n = 49, p< 0.0001) for an
interpulse interval of 20 ms (Figure 3A, B). This resulted
in an increase of the paired-pulse ratio (PPR) which was
significant for interstimulus intervals from 10 ms to
400 ms (control: 0.24 ± 0.04, CCh: 0.69 ± 0.06, interstimu-
lus interval 20 ms; n = 49, p< 0.0001; Figure 3D).
CCh decreases the paired-pulse inhibition via mAChRs
At interpulse intervals between 10 and 30 ms, both atro-
pine (n = 19, p< 0.05 vs. CCh and p> 0.05 vs. control;
Figure 3A, B, C, E) and AFDX (n = 15, p< 0.05 vs. CCh
and p> 0.05 vs. control; Figure 3F) antagonized the
CCh-induced increase in PPR. In contrast, the CCh-
induced increase of the PPR at these interstimulus intervals
was unaltered by addition of pirenzepine (n= 14, p> 0.05
vs. CCh and p< 0.05 vs. control; Figure 3G). Conversely,
application of AFDX (n=6) or atropine (n= 5) prevented
the CCh-induced increase of PPR (p> 0.05 vs. control;
not shown), whereas pirenzepine failed to prevent this
CCh-induced increase of PPR (n = 7, p< 0.05 vs. control;
not shown).
Application of linopirdine had no effect on the PPR
(n=10, p> 0.68; Figure 3H) suggesting that the M-current
blockade is not involved in the CCh-induced increase of
PPR. Additionally, we verified that retigabine (10 μM)
did not alter the PPR (not shown, n = 8, p> 0.05). This
suggests that modulation of GABA release, underlying
the paired-pulse depression, is dominated by M2
mAChR effects. To further rule out the involvement of
M1/M4 mAChRs in the depression of inhibition, we ap-
plied xanomeline. Xanomeline did not alter the PPR
(n = 6, p> 0.05).
CCh decreases inhibitory synaptic conductances via M2
mAChR
To more directly evaluate the effects of mAChRs on syn-
aptic inhibition, we evaluated the synaptic conductances
underlying the IPSPA and IPSPB in the presence of vari-
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Figure 3 Pharmacology of CCh effect on paired-pulse stimulation of field potentials. A, B, C. Example of field potential recordings using a
paired-pulse protocol in control (A), 10 μM CCh (B) and during 10 μM CCh+ 1 μM atropine co-application (C). Note that 10 μM CCh decreased
the paired pulse depression compared to control condition. Co-application of 1 μM atropine with 10 μM CCh reversed this effect. D. Plots of the
paired-pulse ratio (PPR) at different interstimulus intervals (10, 20 and 30 ms), in control and in the presence of 10 μM CCh (n = 49). E - H. The
effects of different mAChR antagonists and of 10 μM linopirdine on CCh-induced alterations of paired-pulse ratio, as indicated. Note that co-
application of 1 μM atropine (E; n = 19) or 2 μM AFDX (F; n = 15) with CCh reversed the CCh-mediated increase of PPR, whereas 1 μM pirenzepine
(G; n = 14) had little effects. Note that linopirdine (H; n = 10) did not mimick the CCh-induced increase of PPR. These experiments were performed
in an ITRC. The symbols represent: *: p< 0.05 vs. control, **: p< 0.01 vs. control, ***: p< 0.001 vs. control; +: p< 0.05 vs. CCh, ++: p< 0.01 vs. CCh,
+++: p< 0.001 vs. CCh.
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components (Figure 4 A,B). Estimating the underlying
conductances (gIPSP) revealed substantial decreases;
gIPSP-A decreased from 110 ± 31 nS to 34 ± 11 nS, gIPSP-B
decreased from 41± 9 nS to 12 ± 3 nS, i.e. by 69.1 and
69.8%, respectively (Figure 4E; n = 17, p< 0.05). To
evaluate which subtypes of mAChRs are involved in this
modulation of inhibition we first tested the M2/M4
mAChRs antagonist AFDX in the presence of CCh. In
these neurones, CCh virtually abolished the conduc-
tances of both IPSPs (gIPSP-A from 32.8 ± 13.6 to 0.0 ± 5.4
nS; n = 5, p< 0.05 and gIPSP-B from 18.7 ± 4.6 nS to
3.5 ± 1.4 nS; n = 5, p< 0.05). Application of AFDX caused
a considerable reversal in the depression of inhibition
recovering to 63 and 72% of the control values (p> 0.05
vs. control).Next we tested the effects of the M1/M4 mAChRs an-
tagonist pirenzepine. Application of CCh considerably
reduced the synaptic conductances, gIPSP-A from
104.3 ± 39.4 nS to 58.9 ± 29.0 nS, gIPSP-B from 25.0 ± 8.2
nS to 13.0 ± 5.3 nS i.e. on average by 44 and 48%. On
addition of pirenzepine, the depression of inhibitory
conductances was essentially unaltered (gIPSP-A: 74.9 nS,
p> 0.05 vs. CCh; gIPSP-B: 15.7 nS p> 0.05 vs. CCh).
To further substantiate our hypothesis of a M2
mAChR-mediated depression of inhibition, we next
tested xanomeline to evaluate possible effects of M1 or
M4 mAChRs. Application of xanomeline (3 μM) had no
consistent effect on Em or Rm (control −75.2 ± 2.0 mV,
26.7± 9.0 MΩ xanomeline: -76.4 ± 1.7 mV, 26.1 ± 9.7 MΩ
p> 0.05). These neurones exhibited the usual alteration of
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Figure 4 Effects of cholinergic compounds on synaptic inhibition. A, B. Voltage traces of a neurone in control conditions and in the presence
of CCh. Orthodromic stimulation elicited compound synaptic responses consisting of an EPSP, IPSPA and IPSPB. The two IPSPs are particularly
obvious at less negative membrane potentials. The membrane potential was altered by current injections (+0.4, 0, -0.4 nA, from top to bottom). B:
Traces from the same neurone in the presence of CCh. Note the marked decrease in the amplitudes of IPSPA and IPSPB in the top trace. C,D: Plot
of the membrane potentials obtained by different current injections (−0.4 to + 0.4, 0.05 nA increment) at different times of the traces shown in A
and B. The different symbols denote the different times indicated in A and B. Note the decrease in IPSPA and IPSPB conductances obvious from
the steeper current voltage relationship. E. Plot of the mean gIPSP-A and gIPSP-B in control and in the presence of CCh as indicated. F. Plot of the
mean gIPSP-B values in control, in the presence of xanomeline (xano) and xanomeline+ CCh. The vertical bars represent the s.e.m.
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25.0± 1.7 to 23.8 ± 1.2). Yet, the gIPSP-A and gIPSP-B were
unaltered (control: 88± 29 nS, 28± 7 nS, xanomeline:
92± 28 nS, 31± 8 nS, respectively, n = 5, p> 0.05, see Fig-
ure 4 F). Addition of 10 μM CCh in the presence of xano-
meline had no further effect on Em or Rm (p> 0.05 vs.
CCh) but greatly reduced both inhibitory conductances,
gIPSP-A decreased to 36±18 nS and gIPSP-B to 9 ± 3 nS, i.e.
by 61.2 and 69.1%, close to the values obtained for CCh
alone. The difference to control was significant for gIPSP-B(p< 0.05), but just not significant for the gIPSP-A
(p=0.057).
Modulation of glutamatergic transmission
Effects of carbachol on excitatory synaptic transmission:
Field potentials and intracellular recordings
In control ACSF, the amplitudes of EPSP and field
potentials increased progressively with increasing stimu-
lus intensities to reach a plateau (Figure 5C, D). Applica-


















































Figure 5 CCh-induced depression of synaptic transmission is due to activation of muscarinic receptors. A, B. Voltage traces of a rat
neocortical neurone (top traces) and simultaneously recorded field potentials (bottom trace) in control condition (A) and in the presence of
10 μM carbachol (CCh) (B). The traces show synaptic responses elicited by orthodromic stimulation (100 μs, 20 V). Note the depressant effect of
CCh on the amplitude of EPSP and field potential. C. Plot of the average EPSP amplitudes vs. stimulus intensity (input–output curve) in control
conditions and in the presence of CCh as indicated (n = 45). D. Plot of the average field potential amplitudes vs. stimulus intensity in control and
in the presence of CCh (n = 42). These experiments were performed in STRC. **: p< 0.01, ***: p< 0.001.
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tials (STRC; n = 42, p< 0.05; Figure 5A, B, D) in a similar
range of stimulus intensities.
The input–output curves of EPSP were well fitted by
the Boltzmann equation yielding a maximal EPSP ampli-
tude (EPSPmax) of 22.6±0.9 mV, a half maximal stimulus
intensity (I50) of 6.71±0.36 V and a slope factor of
1.66±0.14 (n=45). CCh significantly decreased EPSPmax to
16.0±1.1 mV and increased both I50 and slope factor to
9.08±0.44 V and 2.82±0.24, respectively (n=45; p< 0.001),
i.e. the curve became more shallow and I50 shifted to higher
values.
The depression of field potentials by CCh (n = 8) was
completely reversible (p> 0.05 vs. control), whereas that
of EPSPs (n = 11) was partially reversible after washout.
The EPSPmax recovered on average by 66 ± 11% after
washout (p< 0.05 vs. control and CCh), whereas the
effects on I50 and slope factor were completely reversible
(p> 0.05 vs. control, n = 11).
CCh-induced depression of synaptic responses is due to
activation of mAChRs
Atropine (1 μM) alone had no effect on the amplitude of
EPSP or field potentials at all stimulus intensities (2–20 V;
n= 9, p> 0.05; not shown). Also, I50 or slope factor wereunaffected by atropine (not shown), indicating no obvious
steady state modulation of synaptic responses by endoge-
neous mAChRs. Pre-application of atropine prevented the
CCh-induced decrease of EPSPmax as well as the CCh-
induced increase of I50 and slope factor (n= 7, p> 0.05 vs.
atropine or vs. control; Table 1). Conversely, addition of at-
ropine fully reversed the CCh-induced decrease of EPSPmax
and field potential amplitude (n= 7, p> 0.05 vs. control
and p< 0.05 vs. CCh; Table 1). The CCh-induced increase
of I50 and slope factor were also reversed (n=7, p> 0.05
vs. control and p< 0.05 vs. CCh; Table 1). This suggests
that the CCh effects on excitatory synaptic transmission
are mediated by activation of mAChRs.
The CCh-induced depression of synaptic responses is
sensitive to pirenzepine and AFDX
Applied alone, neither pirenzepine (1 μM; n= 10) nor
AFDX (2 μM; n= 11) had detectable effects on the EPSP
amplitude, I50 or slope factor of the input–output curve
(not shown; p> 0.05).
Application of pirenzepine in the presence of CCh
antagonized the CCh-induced decrease of EPSPmax
(n = 9, p> 0.05 vs. control and p< 0.05 vs. CCh; Table 2).
Pirenzepine also antagonized the increase of slope factor
(n = 9, p> 0.05 vs. control and p< 0.05 vs. CCh) and
Table 1 Effects of 10 μM CCh, 1 μM atropine alone, or co-
application of CCh and atropine as indicated on the
maximal amplitude of the field potentials, the maximal
amplitude of EPSP (EPSPmax), the I50 and slope factor of
the EPSP input–output curve
Ctl (n = 7) CCh (n = 7) CCh+ atro (n = 7)
Field max (mV) −0.53 ± 0.17 −0.16 ± 0.05 (*) −0.61 ± 0.15 (+)
EPSP max (mV) 18.8 ± 1.6 11.8 ± 1.6 (*) 19.1 ± 2.2 (+)
I50 (V) 7.25 ± 1.15 8.36 ± 1.11 (*) 6.39 ± 1.13 (+)
Slope factor 1.44 ± 0.41 2.75 ± 0.2 (*) 1.26 ± 0.43 (+)
Ctl (n = 7) atro (n =7) atro+CCh (n= 7)
Field max (mV) −0.63 ± 0.16 −0.73 ± 0.2 (*) −0.78 ± 0.21 (*)
EPSP max (mV) 21± 1.7 21 ± 1.8 21.8 ± 1.9
I50 (V) 9.77 ± 0.78 9.5 ± 0.8 8.92 ± 0.62
Slope factor 2.12 ± 0.36 2.05 ± 0.29 2.26 ± 0.12
The order of two drugs given in the figures indicates the sequence of
application (i.e. “CCh+ atro” means atropine was added to a CCh containing
ACSF and vice versa).
These experiments were performed in STRC.
*: p< 0.05 vs. control, +: p< 0.05 vs. previous condition.
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CCh+Pir:124 ± 12% of control; n = 9, p< 0.05 vs. control
and CCh; Table 2). Application of pirenzepine prior to
CCh, however, failed to prevent the CCh-induced de-
crease of EPSPmax (n = 7, p< 0.05 vs. control or vs. piren-
zepine alone; Table 2). In fact, CCh added to a
pirenzepine-containing ACSF depressed the EPSPmax to
76 ± 6% of control (n = 7), indistinguishable from the de-
pression observed with CCh alone (to 69 ± 4% of the
control; n = 45; p> 0.05). This failure of pirenzepine to
prevent a CCh-induced depression, when applied before
CCh, is in sharp contrast to the pirenzepine effect onTable 2 Effects of 10 μM CCh, 1 μM pirenzepine, or co-
application of CCh and pirenzepine, as indicated, on the
maximal amplitude of the field potentials, the maximal
amplitude of EPSP (EPSPmax), the I50 and slope factor of
the EPSP input–output curve
Ctl (n = 9) CCh (n = 9) CCh+pir (n = 9)
Field max (mV) −0.75 ± 0.25 −0.29 ± 0.16 (*) −0.69 ± 0.24 (+)
EPSP max (mV) 24.3 ± 1.5 20.6 ± 2 (*) 23.6 ± 1.7 (+)
I50 (V) 5.12 ± 0.81 9.23 ± 1.71 (*) 6.22 ± 0.94 (*) (+)
Slope factor 1.61 ± 0.59 4.16 ± 0.95 (*) 1.52 ± 0.40 (+)
Ctl (n =7) pir (n = 7) pir + CCh (n= 7)
Field max (mV) −0.68 ± 0.3 −0.7 ± 0.29 −0.56 ± 0.25 (+)
EPSP max (mV) 20.5 ± 5.3 20.3 ± 5.1 16.0 ± 4 (*) (+)
I50 (V) 8.41 ± 0.75 8.45 ± 0.76 9.37 ± 1.04 (*)
Slope factor 1.93 ± 0.54 2.18 ± 0.68 1.95 ± 0.31
The order of two drugs given in the figures indicates the sequence of
application (i.e. “CCh+ pir” means pirenzepine was added to a CCh containing
ACSF and vice versa).
These experiments were performed in STRC.
*: p< 0.05 vs. control, +: p< 0.05 vs. previous condition.neuronal firing, where pirenzepine is effective irrespec-
tive of the sequence of application.
Application of AFDX in the presence of CCh partly
antagonized the CCh-induced decrease of the EPSPmax
(by 52.3 ± 3.1%; n = 8, p< 0.05 vs. control and CCh;
Table 3). AFDX did not antagonize the effect on I50 or
slope factor (n = 8, p> 0.05 vs. CCh and p< 0.05 vs. con-
trol; Table 3). Also, application of AFDX before addition
of CCh prevented the depressant effect of CCh on EPSP-
max. Indeed, the EPSPmax in the presence of AFDX+CCh
was not different from that measured in the control con-
dition (n = 7, p> 0.05; Table 3). Pre-application of AFDX
also prevented the CCh-induced increase of I50 (p> 0.05
vs. control or AFDX alone) but not the increase of slope
factor (n = 7, p< 0.05 vs. control or AFDX alone). To fur-
ther determine which subtype of mAChR mediates the
effects of CCh on EPSP, we applied xanomeline. Xano-
meline decreased the EPSPmax from 25.6 ± 1.8 mV to
23.2 ± 2.7 mV (n= 12, p< 0.05).
CCh-induced depression of synaptic responses is not
mimicked by M-current blockade
Linopirdine had no effect on the amplitude of the field
potentials (Figure 6A, B, bottom traces, 6D and only mar-
ginally decreased (< 10%) the amplitude of EPSP (Figure 6A,
B, top traces). This effect was only present at higher stimu-
lus intensities (n=12, p< 0.05; Figure 6C). Linopirdine had
no effect on the slope factor but slightly reduced I50 (from
6.9±0.6 V to 6.4±0.6 V; n=12, p< 0.05). Retigabine
(10 μM) had no effect on the maximal amplitude of the
field potentials (control: -0.54±0.13 V, retigabine:
-0.53±0.13 V), on EPSPmax (control: 30.8 ±3.4 V, retigabine:
30.5±4.0 V), or the slope factor (control: 1.01±0.26 V,Table 3 Effects of 10 μM CCh, 2 μM AFDX, or co-
application of CCh and AFDX as indicated on the maximal
amplitude of the field potentials, the maximal amplitude
of EPSP (EPSPmax), the I50 and slope factor of the EPSP
input–output curve
Ctl (n = 8) CCh (n = 8) CCh+AFDX (n= 8)
Field max (mV) −0.36 ± 0.09 −0.1 ± 0.04 (*) −0.26 ± 0.08 (*) (+)
EPSP max (mV) 18.9 ± 1.8 10.9 ± 1.6 (*) 15.2 ± 1.7 (*) (+)
I50 (V) 8.45 ± 0.7 10.9 ± 0.86 (*) 9.65 ± 0.8 (*)
Slope factor 2.29 ± 0.27 3.27 ± 0.48 (*) 2.70 ± 0.33 (*)
Ctl (n = 7) AFDX (n=7) AFDX+CCh (n= 7)
Field max (mV) −0.79 ± 0.17 −0.99 ± 0.24 −0.67 ± 0.23
EPSP max (mV) 22.2 ± 2.4 23.9 ± 1.8 (*) 23 ± 1.8
I50 (V) 7.42 ± 1.11 7.22 ± 1.44 8.94 ± 2.37
Slope factor 1.82 ± 0.67 2.05 ± 0.71 3.07 ± 0.75 (*) (+)
The order of two drugs given in the figures indicates the sequence of
application (i.e. “CCh+AFDX” means AFDX was added to a CCh containing
ACSF and vice versa).
These experiments were performed in STRC.



















































Figure 6 CCh-induced depression of synaptic transmission is not due to blockade of M-current. A, B. Voltage traces (top traces) and field
potentials (bottom traces) of a neocortical neurone in control condition (A) and in the presence of linopirdine (10 μM) (B; stimulus intensity
100 μs, 20 V). Note that linopirdine did not alter synaptic responses. C, D. Plots of average EPSP amplitudes (C; n = 12) and field potentials (D;
n = 12) vs. stimulus intensity in control and in the presence of linopirdine (lino) as indicated. Note that linopirdine application decreased the
amplitude of EPSP only at the highest stimulus intensities. These experiments were performed in STRC. *: p< 0.05.
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retigabine increased I50 (from 11.3±0.8 V to 13.2±0.9 V;
n=8, p< 0.05). These data suggest that CCh–induced de-
pression of maximal field potentials and EPSPmax are
mediated by mAChRs not coupled to KV7 channels.
Discussion
The key findings of this study are: (i) activation of M1
mAChR increased the neuronal AP firing via blockade of
M-current, (ii) activation of M2 mAChR increased the
paired-pulse ratio of field potentials and decreased both
components of GABAergic inhibition, and (iii) activation
of M4 mAChR depressed glutamatergic transmission
presumably via activation of presynaptic receptors.
Methodological aspects
The previous studies investigating the mAChRs in slice
preparations used either sharp microelectrode recordings
[20,30] or whole cell patch clamp recordings
[22,23,31,32]. The latter disturb the intracellular milieu
and a massive rundown of M-current (modulated by
mAChRs) was observed [33], precluding a reliable
pharmacology. Intracellular recordings in cortical slices
with sharp microelectrodes hence present a valuable
method to quantify the effects at native mAChRs in
slices.However, reports in the neocortex focussed on the role
of mAChRs or M-current either on the neuronal firing
[20,30,32], on the GABAergic transmission [23,31] or on
the glutamatergic transmission [22,34]. Only few studies in
cortex e.g. [21] or in hippocampus e.g. [35] investigated
the role of mAChRs on both neuronal firing and synaptic
transmission. The comparison of data obtained in different
preparations using different experimental conditions is
problematic, though. Therefore, in the present study we
investigated the 3 aspects, namely change of firing, depres-
sion of EPSPs and of IPSPs, in the same preparation under
identical experimental conditions.
Although some authors used different concentrations
of mAChRs agonists/antagonists, only one or few stimu-
lus intensities e.g. [22] or current injections e.g. [35] were
used. Therefore, the results were mostly qualitative from
a physiological point of view, precluding quantitative
comparisons of different agonists/antagonists.
Effect of mAChR activation on neuronal excitability
The consistent increase in the slope of neuronal firing by
CCh in the somatosensory cortex is similar to the hippo-
campus [35] and the nucleus gracilis [36]. However, our
determination of slope and intercept provides a more
quantitative analysis of changes of firing compared to
previous observations [35,36]. In particular, these authors
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current intensity before and during substance applica-
tion. The interpretation of such data would be compli-
cated by concomitant alterations of membrane potential
and/or neuronal input resistance.
In any case, alterations of firing are mediated by
mAChRs, as evidenced by the antagonism by atropine.
Moreover, the antagonism by pirenzepine (M1/M4
mAChRs antagonist) but not by AFDX (M2/M4 mAChRs
antagonist) further suggests an effect via M1 mAChR, simi-
lar to the M1 mAChR-mediated repetitive spontaneous
neuronal firing observed in rat prefrontal cortex [21]. Our
conclusion is in line with previous data indicating that ACh
application increases the neuronal firing of neocortical pyr-
amidal neurones in mice lacking M3 or M5 mAChRs but
not in mice lacking M1 mAChR, confirming further an in-
volvement of the M1 mAChR in this effect [37].
The cellular mechanisms underlying the CCh-induced
increase of AP firing can be inferred from the effect of
linopirdine which is an established blocker of KV7 chan-
nels [25]. Linopirdine increased the neuronal firing as in
hippocampus [25] and entorhinal cortex [32]. Together,
these data indicate a M1 mAChR mediated depression of
M-current [38] as the underlying mechanism of CCh-
induced firing increase.
Effect of mAChR activation on GABAergic transmission
We studied the mAChR mediated effect on neurotrans-
mitter release by using the paired-pulse protocol with
field potentials. CCh increased the PPR for interpulse
intervals ranging from 10 to 400 ms. This suggests that
the CCh effect involves both GABAA and GABAB recep-
tor-mediated effects. The CCh-induced increase of the
PPR is most likely due to mAChR-mediated depression
of GABA release [23], and evoked IPSCs [31], during the
first stimulus. Normally, GABA would attenuate the re-
sponse to a second stimulus by decreasing release via
presynaptic GABAB receptors [39,40]. Hence a mAChR-
mediated depression of GABA release might contribute
to the altered paired pulse properties of synaptic
responses.
The involvement of M2 mAChR in the CCh-induced
depression of GABA release underlying increase of
PPR can be inferred from the antagonism by AFDX
(M2/M4 mAChRs antagonist) and lack of antagonism
by pirenzepine (M1/M4 mAChRs antagonist). Similar to
the pharmacology at M1 mAChR, the effects of atro-
pine and AFDX on this M2 mAChR-mediated increase
of PPR were identical whether the antagonist was ap-
plied in the presence of, or before, CCh.
Further evidence was obtained by evaluating the altera-
tions in inhibitory conductance mediated by GABAA and
GABAB receptors. Firstly, the similarity in the depression
of both gIPSP-A and gIPSP-B, indicates a commondenominator for both effects i.e. depression of GABA re-
lease. The effects of the selected compounds revealed
which mAChR is involved in this depression of GABA
release. The CCh effects were considerably antagonized
by the M2/M4 mAChRs antagonist AFDX but slightly by
the M1/M4 mAChRs antagonist pirenzepine. Moreover,
the M1/M4 mAChRs agonist xanomeline had no effects
on gIPSP-A or gIPSP-B, yet subsequent addition of CCh
reduced gIPSP-A and gIPSP. This observation strongly sug-
gests that neither M1 nor M4 mAChRs are involved in
the modulation of GABA release. Together these data
support our view that M2 mAChR are involved in the
modulation of GABA release.
This view is also supported by histological data. M2
mAChRs are predominantly localized at presynaptic
axons of GABAergic neurones and are associated with
asymmetric as well as symmetric cortical synapses [16-
18,23], suggesting that M2 mAChR can modulate GABA
release in the neocortex. In addition, M1 mAChRs are
mainly expressed on cortical pyramidal neurones rather
than by GABAergic neurones [41].
ACh reduces the GABA release in neocortex by two
separate mechanisms i) by decreasing Ca2+ currents via
activation of a M2 mAChR/PI3K/Ca
2+-independent PKC
pathway and to a smaller extent by activation of a M1
mAChR/PLC/Ca2+-dependent PKC pathway [23]. This
combination might explain the relatively large contribu-
tion of the M2 mAChR and the absence of detectable
effects of the M1 mAChR in the CCh-induced increase
of PPR observed here.
Effect of mAChR activation on glutamatergic transmission
Our observation of CCh decreasing the amplitudes of
evoked synaptic potentials is in line with a wealth of evi-
dence from various areas of the rodent brain [22,34-36].
Both field potentials and intracellularly recorded EPSPs
were depressed by CCh to a similar degree. Considering
the marginal changes in Em, this decrease cannot be
accounted for by a membrane depolarization, confirming
results obtained in entorhinal cortex [34]. These authors
reported that the depression of synaptic transmission
persisted when neurones were returned to their initial
resting potential. However, previous observations in
hippocampus e.g. [35] or neocortex e.g. [21,22] com-
pared the synaptic response following a single stimulus
intensity before and during substance application. Our
determination of I50, EPSPmax and slope factor provide a
more quantitative analysis of changes of synaptic trans-
mission, corroborating and extending previous findings.
In particular, the consistent effects over a wide range of
stimulus intensities exclude the possibility of threshold
phenomena.
Our data indicate that this CCh-induced depression of
EPSP is 1) fully prevented when CCh is applied in the
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vented when CCh was applied in the presence of piren-
zepine. This corroborates and extends previous data
from layer V of the somatosensory cortex [22]. Unlike
these authors, applying CCh in the presence of antago-
nists, we also applied the mAChRs antagonists in the
presence of CCh, revealing marked differences with dif-
ferent sequence of application. The CCh-mediated de-
pression of EPSP was fully reversed when pirenzepine or
atropine was added in the presence of CCh, i.e. pirenze-
pine is more effective when applied in the presence of
the agonist. AFDX, however, only partially reversed this
depression, i.e. is less effective when applied in the pres-
ence of the agonist. This peculiarity may contribute to
the discrepancies between previous reports. Usually, the
authors have either applied the antagonist in the pres-
ence of agonist or vice versa, the agonist in the presence
of antagonists. To the best of our knowledge, the two
complementary protocols had not been used in the same
study so far e.g. either addition or pre-application was
used, see [22,42].
We propose that pirenzepine, a M1/M4 prefering
mAChRs antagonist [43], affects the EPSP amplitude via
M4 mAChR for the following reasons:
1) The increase of neuronal firing by CCh was pre-
vented and reversed by pirenzepine. However, the de-
crease of EPSPmax by CCh was reversed but not
prevented by pirenzepine. This difference may suggest
that the pirenzepine-sensitive effects on EPSPmax and on
slope of neuronal firing are mediated by two distinct
mAChRs, i.e. the pirenzepine-sensitive effect on EPSPmax
is not mediated by M1 mAChR.
2) Only M2 and M4 mAChRs (but not M1, M3 and M5
mAChRs) are coupled to G-proteins Gi/Go family
involved in the inhibition of neurotransmitter release
[7,44,45]. In addition, recent evidence indicates that M4
mAChR is the major mAChR subtype responsible for
direct cholinergic modulation of EPSP [46]. Therefore,
the pirenzepine effect on CCh-induced EPSP depression
is probably due to an action of pirenzepine on M4 rather
than M1 mAChRs [43]. This view is supported by immu-
nohistochemical data [17], showing that cortical M1
mAChRs are located exclusively at postsynaptic sites.
3) The effects of atropine and AFDX on the M2
mAChR-mediated increase of PPR were identical regard-
less of the sequence of application. However, the effects
of pirenzepine and AFDX on the CCh-induced decrease
of EPSP were different whether this antagonist is applied
in the presence or before the CCh application. This dif-
ference may suggest that the CCh-induced decrease of
EPSPmax and increase of PPR are mediated by two dis-
tinct mAChRs, i.e. the CCh-induced decrease of EPSPmax
is not mediated by M2 mAChR. Moreover, the increase
of PPR by CCh (mediated by M2 mAChR) was notprevented or reversed by pirenzepine. This suggests that
pirenzepine is not active at M2 mAChR in our
conditions.
4) AFDX applied before CCh or pirenzepine applied in
the presence of CCh can both fully prevent and reverse,
respectively, the CCh-induced depression of EPSPmax.
The similar potency of pirenzepine and AFDX on CCh-
induced EPSPmax depression therefore suggests an in-
volvement of M4 mAChR as the most parsimonious
explanation.
Cholinergic transmission and cognition
Ample evidence suggests that mAChR-mediated signal-
ling in the cortex is critical for learning and memory, yet
the mechanisms of ACh facilitating cognitive processes
remained elusive. The effects reported here, namely the
depression of EPSP and the increased neuronal firing
mediated by different mAChRs would provide a very
interesting system for “attention” at the cellular level.
The M4 mAChR-mediated depression of EPSP reduces
the noise of ongoing synaptic activity while the M1
mAChR-mediated increase of neuronal firing augments
the neuronal response to a given synaptic input, i.e. these
two effects would improve the signal to noise ratio.
Moreover, the shallower input–output curve of synaptic
responses induced by M4 mAChR observed here extends
the subthreshold range for temporal summation, which
is augmented by a CCh-induced reduction of Kir-type
potassium current [21]. In addition, the cholinergic de-
pression of GABA release corresponds to a depression of
inhibition by higher frequencies of stimulation [40]
implicated in long-term potentiation [47]. Together,
these data corroborate and extend a theoretical frame-
work proposed by Hasselmo and McGaughy [48].
Conclusions
Our data provide evidence that the triade of cellular
CCh effects are mediated by three subtypes of mAChR,
i) M1 mAChR-mediated increase of firing, ii) M2
mAChR-mediated depression of GABA release and iii)
M4 mAChR-mediated depression of glutamatergic synap-
tic responses. Activation of these effects by physiologic-
ally released ACh provides an interesting combination of
neuronal attention and facilitation of LTP. In addition,
the three parameters delineated here may present useful
tools to test new M1, M2 or M4 mAChRs modulators at
native receptors in the human neocortex from epilepsy
surgery tissues.
Methods
Tissue handling and preparation
Coronal slices containing the sensorimotor cortex were
made from male Wistar rats (age: 30-42 d). Experiments
were approved by the Berlin health protection agency
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decapitated and a block of brain containing the sensori-
motor cortex was quickly removed. The tissue was cut into
slices (400 μm) with a vibratome (HM 650 V, MICROM
International, Walldorf, Germany) in artificial cerebrospinal
fluid (ACSF, 5± 1°C). The slices were stored submerged at
room temperature in continuously oxygenated (carbogen:
95% O2-5% CO2) ACSF. Slices were allowed to recover for
at least 1 hour before recordings commenced. Individual
slices were transferred to the recording chambers and given
30 min to adapt.
Solutions and substances
ACSF contained (in mM) 124 NaCl, 5 KCl, 2 MgSO4, 2
CaCl2, 1.25 NaH2PO4, 26 NaHCO3 and 10 glucose (pH
7.4, after equilibration with carbogen).
Atropine (Sigma, Taufkirchen, Germany), carbamylcho-
line-chloride (carbachol, CCh; Gift from GlaxoSmithKline),
linopirdine dihydrochloride (Tocris, Bristol, UK) and piren-
zepine (Sigma) were dissolved in H2O. AF-DX 116 (abbre-
viated AFDX, Tocris), retigabine and xanomeline (both gift
from GlaxoSmithKline) were dissolved in DMSO. The final
concentration of DMSO was below 0.1%. Stock solutions
of each drug were prepared and stored at −20°C until use.
The following mAChRs related compounds were used:
pirenzepine (M1/M4 mAChRs antagonist), AFDX 116
(M2/M4 mAChRs antagonist), xanomeline (M1/M4
mAChRs agonist) and atropine (broad spectrum
mAChRs antagonist) [24,43,49]. We refrained from using
mamba toxin 7, a proposed selective blocker of M1
mAChR, because the application via perfusion would be
prohibitively expensive and the stability under our
recording conditions (oxygen, 32°C) is uncertain [com-
municated by a manufacturer]. We chose established
concentrations of agonist and antagonist based on a lit-
erature survey and a few pilot experiments. A concentra-
tion of 10 μM CCh and 1 μM atropine is established in
slices [21,22], and at 1 μM, atropine does not interfere
with nicotinic receptors [50]. The concentrations of pir-
enzepine (1 μM) and AFDX (2 μM) were chosen from
binding experiments [43,49] and are effective on the
CCh-induced depression of PSP in neocortex or hippo-
campus slices for example [22,51]. Pirenzepine at 1 μM
should have a maximal effect at M1 and M4 mAChRs
but not at M2, M3 and M5 mAChRs. AFDX at 2 μM
should have a maximal effect at M2 and M4 mAChRs
but not at M1, M3 and M5 mAChR [49].
From the above considerations, the following predic-
tions can be made with a minimum of compounds: 1) a
M1 mAChR-mediated effect should be antagonized by
pirenzepine but not by AFDX, 2) a M2 mAChR-mediated
effect should be antagonized by AFDX but not by piren-
zepine and 3) a M4 mAChR-mediated effect should be
antagonized by either pirenzepine or AFDX.To reveal more subtle pharmacological differences of
the mAChRs, i.e. effects of activation state, we applied
antagonists either before or during the CCh application.
Electrophysiological recordings
Recording chambers
Experiments were carried out either in an interface-type
recording chamber (ITRC) or in a submersion-type
recording chamber (STRC). The ITRC enables maximal
oxygen supply and improves recordings of evoked field
potentials and was therefore chosen for the paired-pulse
protocol. The STRC provides more stable conditions and
allows a faster equilibration of drugs in the slices [28].
Therefore, STRC was chosen for intracellular recordings.
In ITRC, slices were perfused with oxygenated ACSF
(1.5-2 ml/min; 34 ± 1°C) and the atmosphere was main-
tained by a continuous flow of pre-warmed and humidi-
fied carbogen. In STRC experiments slices were held
between two nylon grids and perfused with a higher flow
rate of oxygenated ACSF (4–5 ml/min; 31 ± 1°C).
All measurements were made at least 30 min (ITRC)
or 15 min (STRC) after drug application to ascertain
steady-state of applied drugs.
Electrodes
For extracellular recordings, filamented borosilicate ca-
pillaries (Hilgenberg, Malsfeld, Germany) were pulled on
a DMZ universal puller (Zeitz, München, Germany). The
pipette resistances were 2–8 MΩ when filled with ACSF.
Sharp microelectrodes for intracellular recordings were
pulled on a Flaming/Brown P87 Puller (Sutter Instru-
ments, Novato, U.S.A.). When filled with 1 M potassium
acetate (pH 7.2, containing also 1 mM KCl and 5 mM
EGTA) the electrodes had resistances between 70 and
120 MΩ.
Extra- and intracellular recordings
The electrodes were positioned under visual control in
neocortical layers II/III. Signals obtained with extracellu-
lar recordings were fed to a high-impedance preamplifier
(EXT-01 C, npi electronic, Tamm, Germany) and pro-
cessed through second-stage amplifiers with filtering
capabilities (DPA 2 F; npi electronic, Tamm, Germany).
The signals obtained with intracellular recordings were
fed to an appropriate amplifier (SEC-05 L, npi electronic,
Tamm, Germany).
We evaluated the current voltage relationship from
families of current injections (between −0.5 nA and
+1.5 nA, increment 0.05 nA, duration 600 ms), to esti-
mate the neuronal input resistance and the firing behav-
iour. Linear regression of the number of APs vs. injected
current in the initial linear range was used to calculate
the slope and the intercept. The former parameter pro-
vides a quantitative index of AP firing behaviour in a
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below the rheobase and was termed sub-rheobase.
Synaptic responses were elicited by electrical stimuli
(0–20 V, increment 2 V, 100 μs duration at 0.1 Hz, in
triplicate) applied via a bipolar tungsten electrode placed
in the deeper cortical layers (V/VI). The peak amplitude
of the initial component represents the excitatory postsy-
naptic potential and will be referred to as EPSP, although
it might be slightly affected by the inhibitory postsynap-
tic potential (IPSP) with a slightly later time to peak (see
Figure 4A). The input–output curves of EPSP were fitted
by the Boltzmann equation:
Y ¼ A1  A2ð Þ= 1þ e xxoð Þ=dx
 
þ A2
yielding the maximal EPSP amplitude (A2, EPSPmax), the
half maximal stimulus (x0, I50) and the slope factor (dx).
Synaptic conductance mediated by GABAA and
GABAB receptors was estimated similar to previous
methods [40,52]. In brief, linear regressions of the
current voltage relation (usually between −0.3 and +0.3
nA) was carried out before the stimulus and at the ap-
parent peak of the early and late inhibitory synaptic
responses (near 20 ms and 150 ms poststimulus). As-
suming synaptic conductances parallel to “resting” mem-
brane conductance, the subtraction of resting membrane
conductance from the total conductance at the peak of
GABAA and GABAB receptor-mediated events yields an
estimate for the two synaptic responses see [40].
To evaluate the effects of mAChR agonists/antagonists
on neurotransmitter release supposedly via presynaptic
sites, we recorded the field potentials during a paired-
pulse protocol in an ITRC. The ratio of amplitude of the
second field potential in relation to the first in response
to identical stimulations (100 μs, 1 mA) was calculated
for different interstimulus intervals (10 ms-1 s) and was
termed paired-pulse ratio (PPR). An intensity of 1 mA
was chosen for this protocol since it induced a maximal
response with pronounced paired-pulse depression in all
slices tested. In addition, we performed input–output
curves, as in STRC. In ITRC, field potentials were elicited
in cortical layers II/III by electrical stimuli (0-1 mA, incre-
ment 0.1 mA, 100 μs duration at 0.1 Hz, in triplicate)
delivered via a bipolar tungsten electrode placed in cortical
layers V/VI.Data acquisition and analysis
Recorded signals were digitized on-line (10 kHz) with a
PC based system (Digidata 1200 and Clampex 9.3 or
Digidata 1440A and Clampex 10.1 software, Molecular
Devices, Sunnyvale CA, USA), stored on hard disk and
analysed off-line (Clampfit 10.1).Our intracellular recordings were from “regular firing”
neurones, as opposed to “fast spiking” or “burst firing”
neurones [53].
Data are presented as mean ± s.e.m., n indicates the
number of cells (only one cell per slice was recorded).
For comparisons, we used paired or unpaired Student’s
t-test. Differences with p< 0.05 were considered
significant.
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